Cargando…
The rationale for druggability of CCDC6-tyrosine kinase fusions in lung cancer
Gene fusions occur in up to 17% of solid tumours. Oncogenic kinases are often involved in such fusions. In lung cancer, almost 30% of patients carrying an activated oncogene show the fusion of a tyrosine kinase to an heterologous gene. Several genes are partner in the fusion with the three kinases A...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5817729/ https://www.ncbi.nlm.nih.gov/pubmed/29455670 http://dx.doi.org/10.1186/s12943-018-0799-8 |